NVAXNovavax, Inc.
Is the business good?
The checks split: nothing decisive, though margins widening.
Mixed fundamental signals. Nine pass/fail tests of year-over-year health from the filings.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is NVAX?
Novavax, Inc. keeps −57% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
Operating margin · Biotechnology median −77% · 12 months to Q2 2026
- Share count, year on year
- −7.1%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 82%
R&D as % of revenue
- Gross margin
- 79%
Gross margin
| Year | Operating margin |
|---|---|
| FY2020 | −88% |
| FY2021 | −147% |
| FY2022 | −33% |
| FY2023 | −58% |
| FY2024 | −36% |
| FY2025 | 40% |
Details›
- Gross margin12 months to Q2 2026
- 79%
- Operating margin12 months to Q2 2026
- −57%
- Net margin12 months to Q2 2026
- −60%
- Free cash flow margin
- −10%
- R&D as % of revenue
- 82%
- Revenue, trailing twelve months
- $414M
- Free cash flow, trailing twelve months
- −$42M
- Net income, trailing twelve months
- −$248M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.